首页|期刊导航|护理学报|淋巴瘤患者报告结局测量工具中最小临床重要差值制定及应用的范围综述

淋巴瘤患者报告结局测量工具中最小临床重要差值制定及应用的范围综述OA

Development and application of minimal clinically important difference in lymphoma patient-reported outcome measures:a scoping review

中文摘要英文摘要

目的 对淋巴瘤患者报告结局测量工具(Patient-Reported Outcome Measures,PROMs)的最小临床重要差值(mini-mal clinically important difference,MCID)进行范围审查,为本土化淋巴瘤特异PROMs的研制、相关MCID的制定和应用提供方向.方法 遵循范围综述的方法学框架,计算机检索7个中英文数据库中相关研究,检索时限均为建库至2025年10月31日.结果 共纳入11篇文献,涵盖8个已公布MCID阈值(范围)的淋巴瘤相关PROMs,可分为疾病通用型、癌症通用型、淋巴瘤特异型和症状特异型4类属性;在MCID制定方面,方法包括锚定法、分布法和文献分析法,指标涉及主观锚(欧洲癌症研究与治疗组织生活质量问卷、癌症治疗功能评估量表、体力状况评分等)、客观锚(国际预后评分、蛋白水平、影像等)和分布法统计量(1/3或1/2标准差、0.2或0.5效应量、1或1.96标准误等);在MCID应用方面,研究集中于淋巴瘤药物治疗效果的评估,暂未涉及该人群的非药物干预.结论 现有淋巴瘤相关PROMs的MCID存在多个来源,因此在实际应用中取值存在差异,且多数MCID的制定未有淋巴瘤患者的参与.未来亟须基于最新概念框架开发本土淋巴瘤特异PROMs,在充足样本中制定其MCID;同时积极将MCID作为评价指标,拓展至药物和非药物干预研究中,以提升结果的可解释性和临床意义.

Objective To conduct a scoping review of the Minimal Clinically Important Difference(MCID)for Patient-Reported Out-come Measures(PROMs)in lymphoma patients,and to provide guidance for the development of localized lymphoma-specific PROMs and the establishment and application of relevant MCID.Methods Following the methodological framework of scoping review,a com-puterized search was conducted across 7 databases for relevant studies,with a retrieval period spanning from database inception to 31 October 2025.Results A total of 11 studies were included,covering 8 lymphoma-related PROMs for which MCID have been pub-lished;these can be categorised into 4 types:disease-general,cancer-general,lymphoma-specific and symptom-specific;Regarding the establishment of MCID,the methods employed included the anchoring method,the distribution method and the literature analysis method,with indicators involving subjective anchors(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30,Functional Assessment of Cancer Therapy-General,Performance Status,etc.),objective anchors(International Prognostic Index,protein levels,imaging,etc.)and statistical measures derived from the distribution method(1/3 or 1/2 standard devia-tion,0.2 or 0.5 effect size,1 or 1.96 standard error,etc.);regarding the application of MCID,research has focused on the evaluation of the efficacy of drug treatments for lymphoma and has not yet addressed non-pharmacological interventions in this population.Conclusion Currently,the MCID for lymphoma-related PROMs are derived from multiple sources,leading to variations in their ap-plication in practice;furthermore,most MCID were established without the involvement of lymphoma patients.There is an urgent need to develop lymphoma-specific PROMs based on the latest conceptual frameworks and to establish their MCID using sufficiently large sample sizes.At the same time,MCID should be actively adopted as evaluation metrics and extended to studies of both pharmacological and non-pharmacological interventions,in order to enhance the interpretability and clinical significance of the results.

余姗姗;陈昱霆;张玉玺

南京中医药大学 护理学院,江苏 南京 210023南京中医药大学 护理学院,江苏 南京 210023南京中医药大学 护理学院,江苏 南京 210023||南京医科大学第一附属医院(江苏省人民医院),江苏 南京 210029

医药卫生

淋巴瘤患者报告结局测量工具最小临床重要差值心理测量属性范围综述

lymphomapatient-reported outcomemeasurement toolsminimal clinically important differencepsychometric prop-ertiesscoping review

《护理学报》 2026 (10)

46-52,7

江苏省干部保健科研课题面上课题(BJ24002)

10.16460/j.issn2097-6569.2026.10.046

评论